Macquarie Group LTD Chemo Centryx, Inc. Transaction History

Macquarie Group LTD

$90.3 Billion
Q3 2024

Shares

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 Nov 14, 2022	SELL	$22.17 - $51.8 $8,069 - $18,855	-364 Reduced 45.84%	430 $77,000
Q4 2021 Feb 11, 2022	SELL	$18.38 - $40.5 $10,347 - $22,801	-563 Reduced 41.49%	794 $29,000
Q2 2021 Aug 13, 2021	SELL	$9.59 - $50.88 $12.3 Million - $65.2 Million	-1,282,351 Reduced 99.89%	1,357 $18,000
Q1 2021 May 14, 2021	BUY	$49.53 - $68.4 $13.2 Million - $18.2 Million	265,553 Added 26.08%	1,283,708 $65.8 Million
Q4 2020 Feb 16, 2021	BUY	$47.25 - $65.16 $7.47 Million - $10.3 Million	158,063 Added 18.38%	1,018,155 $63 Million
Q3 2020 Nov 13, 2020	BUY	$46.35 - $61.69 $17.4 Million - $23.2 Million	376,054 Added 77.69%	860,092 $47.1 Million
Q2 2020 Aug 11, 2020	BUY	$38.58 - $65.07 $3.78 Million - $6.37 Million	97,962 Added 25.37%	484,038 $27.9 Million
Q1 2020 May 15, 2020	BUY	$32.73 - $50.78 $12.6 Million - $19.6 Million	386,076 New	386,076 $15.5 Million
Q1 2019 May 15, 2019	SELL	$10.01 - $13.89 $38,038 - $52,782	-3,800 Closed	0 $0
Q4 2018 Feb 15, 2019	SELL	$9.15 - $12.26 $8,235 - $11,034	-900 Reduced 19.15%	3,800 $41,000
Q3 2018 Nov 15, 2018	SELL	$10.49 - $13.72 $54,548 - $71,344	-5,200 Reduced 52.53%	4,700 $59,000
Q2 2018 Aug 14, 2018	BUY	$10.62 - $13.98 $105,137 - $138,402	9,900 New	9,900 $130,000
Q1 2018 May 11, 2018	SELL	$5.9 - $14.99 $8,850 - $22,485	-1,500 Closed	0 $0
Q4 2017 Feb 15, 2018	SELL	$5.53 - $8.42 $39,434 - $60,043	-7,131 Reduced 82.62%	1,500 $9,000
Q3 2017 Nov 08, 2017	BUY	$6.5 - $10.69 $56,101 - $92,265	8,631	8,631 $64,000

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Macquarie Group LTD with notifications on news.